ERBB2 and breast carcinoma: The MONALEESA-2 trial demonstrated that ribociclib plus letrozole significantly improved progression-free survival, compared with placebo plus letrozole as a first-line therapy in postmenopausal patients with HR-positive, HER2-negative advanced breast cancer [15].